BEVITAL AS

Inflammation &
Immune Activation

16 biomarkers and metabolites of 3 different classes from 120μl sample volume on LC-MS/MS. New protein markers will be included soon. Contact our experts for any questions or inquiries.
Request a Quote

Home > Molecular Markers > Ready-to-Run > Inflammation & Immune Activation Panel

Why did we design this panel?

We developed this targeted metabolomics panel for investigating inflammation and immune activation to precisely quantify specific metabolites, identify reliable biomarkers, and gain insights into underlying biochemical pathways. This approach supports basic, clinical and epidemiological research as well as:

Early Detection of Inflammatory Conditions: The panel helps detect inflammation-related diseases early, such as autoimmune diseases, infections, cardiovascular diseases, and certain cancers, even before symptoms become prominent.
Precise Diagnosis: By measuring multiple inflammation-related markers, this panel allows for more accurate differentiation between types of inflammatory conditions, improving diagnostic accuracy.
Monitoring Disease Activity: Longitudinal analysis can track the level and progression of inflammation, which is particularly useful in chronic conditions like rheumatoid arthritis, inflammatory bowel disease, and lupus.
Evaluating Treatment Effectiveness: The inflammation panel assists in assessing how well a treatment is working by showing changes in inflammation levels, allowing clinicians to adjust therapies to the individual’s needs.
Reducing Risk of Disease Complications: Chronic inflammation is linked to complications such as cardiovascular disease and organ damage. The panel can help to identify and mitigate these risks early.
Enhancing Personalized Medicine: The inflammation panel provides insights into the specific inflammatory pathways active in an individual, enabling more targeted treatment choices.
Integration with Other Health Data: When combined with other panels or omics data, this panel provides a broader understanding of an individual’s health, helping uncover the underlying causes of inflammation and informing preventive or therapeutic approaches.

Applications: Autoimmune diseases, cancer, cardiovascular diseases, chronic inflammatory diseases, chronic kidney disease, infectious diseases, metabolic disorders, neurodegenerative diseases, pulmonary diseases.

Kynurenines

12 markers by LC-MS/MS

Kynurenines are pivotal in numerous physiological processes, including immune regulation, neurotransmission, redox balance, energy metabolism, mental health, and cancer biology. Kynurenine (Kyn) is formed from the essential amino acid tryptophan (Trp). One enzyme involved in this reaction is indolamine 2,3-dioxygenase (IDO), which is upregulated by various cytokines, in particular INF-gamma. This explains why immune activation leads to formation of kynurenine and depletion of tryptophan. Thus, the kynurenine/tryptophan ratio (KTR) is a marker of cellular (Th-1 type) immune response.

3-Hydroxykynurenine, 3-Hydroxyanthranilic acid, Anthranilic acid, Kynurenine, Kynurenic acid, Nicotinic acid, Nicotinamide, N1-methylnicotinamide, Picolinic acid, Quinaldic acid, Quinolinic acid, Xanthurenic acid, Kynurenine/tryptophan ratio

Neopterin

1 marker by LC-MS/MS

Neopterin, a pyrazino-pyrimidine compound, is synthesized by monocytes and macrophages in response to interferon-𝛾 (IFN-γ) produced by activated T-cells. Both total neopterin and neopterin reflect cellular immune response, because IFN-γ induces a step that precedes formation of 7,8-dihydroneopterin in the neopterin pathway. Increased concentrations are observed in infections, autoimmune diseases, malignant tumour diseases and in allograft rejection episodes. Neopterin in serum/plasma shows a strong, positive relation to total homocysteine and to the kynurenine/tryptophan ratio (KTR).

PAr index

3 markers by LC-MS/MS

PAr index is the ratio of 4-pyridoxic acid divided by the sum of pyridoxal 5´-phosphate plus pyridoxal (PA:(PLP+PL)). Inflammatory markers account for more than 90 % of the explained variance of PAr, which efficiently discriminates subjects with high inflammatory status. It is only slightly influenced by vitamin B6 intake and reflects increased vitamin B6 catabolism during inflammation.

PAr index (PLP, PL, PA)

Proteins

Under development

CRP is produced in hepatocytes, mainly under the transcriptional control of cytokines, IL-6 and IL-1. CRP is a major acute-phase reactant and the most important marker for the diagnosis of systemic inflammation in clinical practice. During an acute immune response, levels can increase more than 1000-fold and peak after about 48 h. Low levels of the so-called high-sensitivity (hs- ) CRP below 10 μg/mL are typically found in the general population. Serum amyloid A (SAA) is another key acute-phase protein and is coded by four different genes. SAA production occurs in the liver and is driven by IL- 6, IL-1, and TNF-α. During acute inflammation, SAA is secreted into the circulation where concentrations could increase more than 1000-fold compared to normal values of <5 μg/mL. Calprotectin is a heterocomplex of S100A8 and S100A9, and belongs to endogenous danger-associated molecular patterns (DAMPs) which are intracellular molecules that amplify an immune response and promote inflammation by interaction with Toll-like receptors (TLRs) and receptors for advanced glycation end products (RAGE). Elevated blood levels have been associated with various inflammatory diseases, such as rheumatoid arthritis, atherosclerosis, CVD, metabolic syndrome, and different types of cancer.

C-Reactive protein, Calprotectin, Serum Amyloid A

Scroll to Top
Linkedin Md-email

Per Christian Eriksen

Md-email

Beate

Md-email

Øivind

Linkedin Md-email

Per Magne Ueland has been Professor at the University of Bergen 1987-2018. He is one of the founders of Bevital AS and the scientific advisor in Bevital since 2023. His interests includes biomarkers related to nutrition, inflammation, ageing and life-style related chronic diseases. Per is committed to the development of precise, high-throughput mass spectrometry methods, tailored for metabolic profiling of biobank specimens from large cohorts.

Md-email

Ove

Linkedin Md-email

Lena

Linkedin Md-email

Marit holds a degree in chemical engineering from Bergen Ingeniørhøyskole, which is now part of the Western Norway University of Applied Sciences. She works with quantitative analysis and method development on LC-MS/MS at the laboratory of Bevital AS.

Linkedin Md-email
Randi  
Linkedin Md-email

Ove completed a bachelor’s degree in Biomedical Laboratory Sciences at the Western Norway University of Applied Sciences in Bergen. With extensive experience in method development and expertise in GC-MS/MS, he specializes in optimizing analytical techniques for research-focused studies. At Bevital, Ove is dedicated to advancing laboratory methods and workflows, contributing to innovative research through precise and reliable analytical solutions.

Linkedin Md-email

Lene holds a bachelor’s degree in Biomedical Laboratory Science from the Western Norway University of Applied Sciences, where she is also completing her master’s degree in Medical Laboratory Technology. At Bevital, she works with GC-MS/MS analyses, focusing on accurate and reliable testing of biological samples. With her strong laboratory background, Lene is committed to delivering high-quality results that support medical research.

Linkedin Md-email

Klaus holds a PhD in physics from the University of Münster in Germany. He has over three decades of experience in Time-of-Flight mass spectrometry. He leverages his extensive expertise to provide customers with cutting-edge MALDI-MS analysis and the newest Olink Proteomics services.

Linkedin Md-email

Adrian holds a PhD in diabetes research, along with bachelor’s and master’s degrees in biomedical science and public health, respectively. With over 20 years of experience in laboratory science, he leads high-precision metabolite analyses and method development at Bevital. His expertise centers on quantifying biomarkers, metabolite classes, and metabolic pathways related to nutrition, cardiovascular and neurodegenerative diseases, and cancer. Adrian is committed to advancing research quality and actively collaborates nationally and internationally, leveraging targeted metabolomics to support innovative, multidisciplinary research.

Statistical power is the probability that a statistical test will correctly reject a false null hypothesis (H0​) when a specific alternative hypothesis (H1​) is true. H0​ is the null hypothesis, which states there is no effect or no difference. H1​ is the alternative hypothesis, which states there is a real effect or difference. Alpha (α) is the probability of a Type I error (a false positive), which is the risk of incorrectly rejecting the H0​ when it is actually true. You set this value before the experiment, commonly at 0.05. Beta (β) is the probability of a Type II error (a false negative), which is the risk of failing to reject the H0​ when it is actually false.

Power is calculated as 1−β. Increasing power means you are decreasing the probability of making a Type II error.

Several factors can be adjusted to increase the power of a statistical test:

  • Effect Size: This is the magnitude of the difference you are trying to detect. A larger effect size is easier to detect, thus increasing power. 

  • Sample Size: The number of observations in a study. A larger sample size provides more information about the population, reducing the margin of error and increasing the power to detect a true effect.

  • Variation: Refers to the spread or standard deviation of the data within the population. Less variation makes it easier to distinguish a real effect from random noise, thereby increasing power.

  • Alpha (): Increasing the alpha level (e.g., from 0.05 to 0.10) also increases power, but at the cost of a higher risk of a Type I error. This trade-off is often undesirable.

562 entries « ‹ 29 of 29 › »
561.

Vollset, S E; Nygârd, O; Refsum, H; Ueland, P M

Coffee and homocysteine Miscellaneous

2000, ISSN: 0002-9165.

Links | BibTeX

562.

Schneede, J; Refsum, H; Ueland, P M

Biological and environmental determinants of plasma homocysteine Journal Article

In: Semin Thromb Hemost, vol. 26, no. 3, pp. 263–279, 2000, ISSN: 0094-6176.

Abstract | Links | BibTeX

562 entries « ‹ 29 of 29 › »

Olink Proteomics

Please fill out the fields below (*required).
We will respond to you ASAP.
Thank you!

Customized analyses

Please fill out the fields below (*required).
We will reply to you soon for a detailed project discussion.
Thank you for reaching out to Bevital!

Mix-and-Match

Please fill out the fields below (*required).
We will respond to you as soon as possible.

Ready-to-Run

Please fill out the fields below (*required).
We will respond ASAP.
Thank you!

Thanks for joining!

Get updates about new method developments, publications and comming events.

Ulvik et al.